CAS NO: | 67469-78-7 |
包装 | 价格(元) |
10mg | 电议 |
25mg | 电议 |
50mg | 电议 |
Cas No. | 67469-78-7 |
别名 | 伐诺司林二盐酸盐,GBR-12909 dihydrochloride; I893 dihydrochloride |
化学名 | 1-(2-(bis(4-fluorophenyl)methoxy)ethyl)-4-(3-phenylpropyl)piperazine dihydrochloride |
Canonical SMILES | FC1=CC=C(C(OCCN2CCN(CC2)CCCC3=CC=CC=C3)C4=CC=C(F)C=C4)C=C1.Cl.Cl |
分子式 | C28H34Cl2F2N2O |
分子量 | 523.49 |
溶解度 | DMF: 2 mg/ml,DMSO: 2 mg/ml |
储存条件 | Store at -20°C |
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
产品描述 | Vanoxerine is an antagonist of dopamine transporter (DAT1) with Ki value of 16.9nM [1]. As an antagonist of DAT, vanoxerine is developed for treatment of Parkinson's disease and depression but has no effect on these diseases. Vanoxerine is also found to have desirable cardiac antiarrhythmic properties. It is a blocker of cardiac hERG (hKv11.1) with IC50 value of 0.84nM. It also blocks the ICa,L and hNav1.5 channel with IC50 values of 320nM and 830nM, respectively. Vanoxerine does not significantly prolong Purkinje fiber APD60 and APD90 and has no significant effect on QT or TDR. Further, the clinical trial demonstrates that the effective concentrations of vanoxerine are well tolerated and safe in man [2]. References: |